Last reviewed · How we verify
NCT07399561: EX-CIPN
Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy
NA trial testing Exercise Intervention in Peripheral Neuropathy, Secondary to Drugs or Chemicals in 140 participants. Not yet recruiting.
1 July 2027
Quick facts
| Lead sponsor | National Cancer Center, Korea |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 140 |
| Start date | 3 February 2026 |
| Primary completion | 1 July 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Exercise Intervention
- Usual Care
Conditions studied
- Peripheral Neuropathy, Secondary to Drugs or Chemicals — all drugs for Peripheral Neuropathy, Secondary to Drugs or Chemicals →
- Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients — all drugs for Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients →
- Paclitaxel Induced Neuropathy — all drugs for Paclitaxel Induced Neuropathy →
Sponsor
National Cancer Center, Korea
Who can join
Adults 19 to 75, any sex, with Peripheral Neuropathy, Secondary to Drugs or Chemicals or Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and often persistent adverse effect of oxaliplatin- and paclitaxel-based chemotherapy. While exercise is frequently recommended for patients with CIPN, it remains unclear whether exercise mitigates neuropathic injury itself or primarily improves physical function and quality of life. This randomized controlled trial evaluates the effects of exercise on CIPN during and after chemotherapy. Patients receiving oxaliplatin for colorectal cancer or paclitaxel for gynecologic cancer are randomized to an exercise intervention or usual-care control. Neuropathy severity is assessed using objective neurophysiological measures, blood biomarkers, and validated clinical and patient-reported outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07399561
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Exercise Intervention
Trials testing the same drug.
- NCT07474090 — Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial · NA · not yet recruiting
- NCT06565260 — Community-Based Exercise and Nutrition Training and Education Program for Cancer Survivors · NA · recruiting
- NCT07302230 — Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Amon · NA · recruiting
- NCT07340281 — Biomarkers for Exercise · NA · recruiting
- NCT07504835 — GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer · NA · not yet recruiting
Other National Cancer Center, Korea trials
Trials by the same sponsor.
- NCT07121478 — Patients With High-grade Pancreatic Neuroendocrine Tumors · Phase 2 · enrolling by invitation
- NCT07171528 — Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer · Phase 2 · recruiting
- NCT07125924 — Intravesical Hyaluronic Acid (HA) for Preventing Radiation Cystitis on Bladder Cancer · NA · not yet recruiting
- NCT07041515 — Knowledge-enhanced Digital Intervention to Prevent Low Anterior Resection Syndrome · NA · not yet recruiting
- NCT07038174 — A Study to Evaluate the Effectiveness of a Web-based Tool for Fertility Preservation in Cancer Patients · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07399561 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Center, Korea
- Last refreshed: 10 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07399561.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing